FDA Grants Priority Review for ImClone's Erbitux

Drug Industry Daily
KEYWORDS Drug Approvals / FDA
A A

The FDA has granted priority review to ImClone Systems' supplemental biologics license application (sBLA) for Erbitux, which seeks approval to sell the drug as a treatment for head and neck cancer.

To View This Article:

Login

Subscribe To Drug Industry Daily